The nurse is caring for a patient with Parkinson’s disease. While writing the care plan for this patient what would be an appropriate nursing diagnosis?

A) Decreased sweating, decreased BP, and increased heart rate: This combination does not reflect a typical stress response. In stressful or threatening situations, the body activates the sympathetic nervous system, leading to increased sweating, elevated blood pressure, and other physiological changes, rather than a decrease in blood pressure.
B) Increased sweating, decreased respiratory rate, and increased BP: In a stressful situation, sweating would indeed increase due to the activation of the sympathetic nervous system. However, the respiratory rate would typically increase, not decrease, as the body prepares for the "fight or flight" response. Increased blood pressure is expected, but decreased respiratory rate does not align with this response.
C) Pupil constriction, increased respiratory rate, and decreased heart rate: Pupil constriction is not characteristic of the "fight or flight" response; instead, pupil dilation occurs as part of the body's preparation to react to a threat. Increased respiratory rate and heart rate are typically seen during stress, but decreased heart rate would not be expected in such a situation.
D) Increased blood pressure, increased heart rate, and pupil dilation: This is the correct response. When faced with a threatening situation, the body activates the sympathetic nervous system, triggering the "fight or flight" response. This includes increased blood pressure and heart rate to prepare the body for action, as well as pupil dilation (mydriasis) to enhance vision and perception of the environment. These changes help the body respond quickly to a perceived danger.

A) Celecoxib (Celebrex):
Celecoxib is a selective COX-2 inhibitor that targets the cyclooxygenase-2 enzyme, which is primarily responsible for inflammation, pain, and fever. COX-2 inhibitors tend to cause less gastrointestinal irritation compared to nonselective NSAIDs like aspirin, which block both COX-1 and COX-2 enzymes. Because aspirin is causing gastrointestinal upset, switching to Celecoxib, which is less likely to irritate the stomach lining, may be an appropriate option to prevent myocardial infarction while minimizing gastrointestinal discomfort.

B) Enteric-coated aspirin:
Enteric-coated aspirin is designed to dissolve in the small intestine rather than the stomach, which may reduce some gastrointestinal irritation. However, it does not eliminate the risk entirely, and it still functions as a COX-1 inhibitor. If the patient is already experiencing gastrointestinal upset, simply switching to enteric-coated aspirin may not be sufficient to alleviate the discomfort, and other options should be considered.

C) Nabumetone (Relafen):
Nabumetone is a nonsteroidal anti-inflammatory drug (NSAID) with some COX-2 selectivity. While it may cause less gastrointestinal upset than non-selective NSAIDs like aspirin, it is still an NSAID and carries a risk of gastrointestinal side effects, especially with prolonged use.
D) A COX-2 inhibitor:
While COX-2 inhibitors, including Celecoxib, are typically effective in reducing inflammation and pain with fewer gastrointestinal side effects than traditional NSAIDs, the term "a COX-2 inhibitor" could refer to various drugs, and Celecoxib (Celebrex) is the most commonly used.